Truist analyst Richard Newitter lowered the firm’s price target on Treace Medical (TMCI) to $4 from $7 and keeps a Hold rating on the shares after its Q3 results and updated outlook. The guide-down implies a return to negative revenue growth in Q4 as contribution from new osteotomy product launches are masked by incremental share loss in core lapiplasty, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical’s Earnings Call: Growth Amid Challenges
- Treace Medical price target lowered to $5 from $6 at Stifel
- Treace Medical price target lowered to $7.50 from $12 at Lake Street
- Treace Medical price target lowered to $5.85 from $6.50 at UBS
- Treace Medical downgraded to Neutral from Buy at BTIG